TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06514365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPACK block with Bupivacaine 0.25% with adrenaline
Description: The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPACK block with Bupivacaine 0.25% with adrenaline
Description: The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
Study: NCT02314130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary therapy
Description: A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
Study: NCT01012531

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injections with highly polymerized allergen extract
Description: cluster schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous injection with placebo
Description: cluster schedule
Study: NCT04088617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
Study: NCT00398476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate (FP)
Description: 200 micrograms (mcg); an aqueous suspension of microfine FP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate (FF)
Description: 110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
Study: NCT00333437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study: NCT02131753

Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine s.c. injection, HCL treatment
Description: Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
Study: NCT02017782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dust
Description: Dust (250-300µg/m3),

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dust
Description: Dust (250-300µg/m3),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: (0,1ppm ozone),

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: (0,1ppm ozone),

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dust and Ozone
Description: Active Dust (250-300 ug/m3)+Ozone(0,1ppm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Filtered air)
Description: Placebo treatment (Filtered air \<20 ug/m3)
Study: NCT00220311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: 6 cycles (1 cycle: 5 treatment days every 28 days)
Study: NCT04524351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solid oral dosage form, capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solid oral dosage form, capsule
Study: NCT01869231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil and chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil and chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil and chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil and chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Study: NCT00123188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound and Biopsy
Description: Transvaginal ultrasound and Endometrial Biopsy
Study: NCT01869231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Study: NCT05371262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
Study: NCT00594581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Juvista (avotermin) plus placebo, standard-care (within-subject controls)
Description: Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Juvista (avotermin) plus placebo, standard-care (within-subject controls)
Description: Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
Study: NCT02780206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope amino acid infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study: NCT02468973

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life style counseling
Description: Life style counseling for chronic patients by medical students
Study: NCT00846573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
Study: NCT00784004

Intervention type: OTHER
Group type: OTHER
Intervention: Breathing Patterns
Description: All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only

Intervention type: OTHER
Group type: OTHER
Intervention: Breathing Patterns
Description: All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only
Study: NCT01189162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV with SLE ventilator vs HFNC via Vapotherm
Description: Nasal respiratory support for RDS
Study: NCT00738972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: 40 mg pravastatin. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg simvastatin. Duration: 12 months. Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Study: NCT01335958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC5754A
Description: Escalating intravenous dose
Study: NCT04688671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-018810
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02436161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management program PROMIC
Description: intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
Study: NCT02788435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Absolute Voice Rest
Description: Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
Study: NCT00846573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
Study: NCT04095338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: Each session will include 50 minutes of traditional physical rehabilitation therapy
Study: NCT04941820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pharmacist intervention
Description: clinical pharmacist intervention
Study: NCT03751501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green-Guided Targeted Laser photocoagulation
Description: Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Therapeutic procedure used in ophthalmology
Study: NCT03752697

Intervention type: BEHAVIORAL
Intervention: metacognitive performance
Description: Paper and pencil/computerized tests of metacognition

Intervention type: BEHAVIORAL
Intervention: metacognitive performance
Description: Paper and pencil/computerized tests of metacognition
Study: NCT01736592

Intervention type: DRUG
Group type: OTHER
Intervention: Long term follow up in all patients who received SAR422459 in previous study TDU13583
Description: Blood draw for the laboratory assessment
Study: NCT02441010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: meridian therapy instrument
Description: The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: meridian therapy instrument
Description: The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
Study: NCT00839358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin
Description: albumine 40 g every 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albumin
Description: albumine 40 g every 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study: NCT00634946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated into the nucleus pulposus of an intervertebral disc.
Study: NCT03983980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof
Description: Tapinarof cream, 1%, applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream applied once daily
Study: NCT02766270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study: NCT02084225

Intervention type: PROCEDURE
Intervention: ultrasound guided regional nerve block
Description: participants were the physicians performing the procedure
Study: NCT03901313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
Study: NCT03374774

Intervention type: DRUG
Intervention: BIAsp 30
Description: Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
Study: NCT03901313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
Study: NCT00741000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Stairstep
Description: Cervical low force mobilization procedure.
Study: NCT03275493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Express a Second Generation 4-1BB: CD19 CAR-T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells with CRS suppression technology
Description: Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
Study: NCT02271633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate
Study: NCT02627690

Intervention type: OTHER
Intervention: islet transplanted
Description: islet transplantation

Intervention type: OTHER
Intervention: non islet transplanted
Description: no islet transplantation (for a non nephrologic reason)
Study: NCT04333316

Intervention type: PROCEDURE
Group type: OTHER
Intervention: large head
Description: implantation of large head total hip

Intervention type: PROCEDURE
Group type: OTHER
Intervention: large head
Description: implantation of large head total hip

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dual mobility cup
Description: implantation of dual mobility total hip
Study: NCT02271633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice